Advances in pharmacotherapy for treating female sexual dysfunction

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2015-03-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2015.1020791PMID 25732267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drugs in early clinical development for the treatment of female sexual dysfunction

  2015cited by this paper
• All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.

  2015cited by this paper
• Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study.

  2015cited by this paper
• Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence

  2015cited by this paper
• Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

  2015cited by this paper
• Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.

  2014cited by this paper
• Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.

  2014cited by this paper
• Flibanserin for female sexual dysfunction.

  2014cited by this paper
• Androgen treatment of postmenopausal women.

  2014cited by this paper
• Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial.

  2014cited by this paper
• Attitudinal Survey of Women Living with Low Sexual Desire

  2014cited by this paper
• The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.

  2014influential reference
• Response to "toward personalized sexual medicine: where is the evidence?".

  2014cited by this paper
• Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial

  2014cited by this paper
• The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy

  2014cited by this paper
• Toward personalized sexual medicine: where is the evidence?

  2014cited by this paper
• Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses From a Phase 2B Dose-Ranging Study

  2014cited by this paper
• Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial.

  2014cited by this paper
• Two novel combined drug treatments for women with hypoactive sexual desire disorder.

  2014cited by this paper
• Bremelanotide for Female Sexual Dysfunctions: Responder Analyses From a Phase 2B Dose-Ranging Study

  2014cited by this paper
• Distress Reduction in Female Sexual Dysfunctions: A Dose-Ranging Study of Subcutaneous Bremelanotide

  2014cited by this paper
• Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial

  2014influential reference
• Sexual dysfunction associated with major depressive disorder and antidepressant treatment

  2014cited by this paper
• Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause

  2014cited by this paper
• Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review

  2014cited by this paper
• Animal models of female sexual dysfunction: basic considerations on drugs, arousal, motivation and behavior.

  2014cited by this paper
• The pharmacology of the human female orgasm - its biological and physiological backgrounds.

  2014cited by this paper
• Effect of food and drug administration decisions on sexual medicine research.

  2014cited by this paper
• Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin

  2014influential reference
• Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies

  2014cited by this paper
• Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples.

  2014cited by this paper
• Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.

  2014influential reference
• The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners.

  2013cited by this paper
• Standard operating procedures for female orgasmic disorder: consensus of the International Society for Sexual Medicine.

  2013cited by this paper
• Hypoactive Sexual Desire Disorder in Women: Treatment Options Beyond Testosterone and Approaches to Communicating with Patients on Sexual Health

  2013cited by this paper
• Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1).

  2013cited by this paper
• A standardized diagnostic interview for hypoactive sexual desire disorder in women: standard operating procedure (SOP Part 2).

  2013cited by this paper
• Hormone therapy for sexual function in perimenopausal and postmenopausal women.

  2013cited by this paper
• Strategies for managing sexual dysfunction induced by antidepressant medication.

  2013cited by this paper
• Listening to placebo in clinical trials for female sexual dysfunction.

  2013cited by this paper
• Profile of Ospemifene in the Breast

  2013cited by this paper
• Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health

  2013cited by this paper
• Arriving at the diagnosis of female sexual dysfunction.

  2013cited by this paper
• Managing female sexual dysfunction.

  2013influential reference
• Androgen therapy in women, beyond libido

  2013cited by this paper
• Psychological and interpersonal dimensions of sexual function and dysfunction

  2013cited by this paper
• Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder.

  2013cited by this paper
• Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy

  2013influential reference
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

  2013cited by this paper
• Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.

  2013cited by this paper
• Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues.

  2013cited by this paper
• Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy

  2013cited by this paper
• A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain.

  2013cited by this paper
• Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms.

  2013cited by this paper
• Contemporary treatment of sexual dysfunction: reexamining the biopsychosocial model.

  2013cited by this paper
• Pharmacogenomics and sexuality: a vision

  2013cited by this paper
• Standard operating procedures for female genital sexual pain.

  2013cited by this paper
• Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.

  2012cited by this paper
• Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.

  2012cited by this paper
• Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.

  2012cited by this paper
• An update on the pharmacological management of female sexual dysfunction

  2012cited by this paper
• EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.

  2012cited by this paper
• What we don't talk about when we don't talk about sex: results of a national survey of U.S. obstetrician/gynecologists.

  2012cited by this paper
• A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder.

  2012cited by this paper
• Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.

  2012cited by this paper
• The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI

  2012influential reference
• Management strategies in SSRI-associated sexual dysfunction in women at midlife

  2012cited by this paper
• The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study

  2012influential reference
• Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

  2011cited by this paper
• Vaginal DHEA to treat menopause related atrophy: a review of the evidence.

  2011cited by this paper
• Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction.

  2011cited by this paper
• Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

  2011cited by this paper
• DHEA Replacement for Postmenopausal Women

  2011cited by this paper
• Reaction to the recent publication by Rosemary Basson entitled ‘Testosterone therapy for reduced libido in women’

  2011cited by this paper
• Women's sexual pain disorders.

  2010cited by this paper
• A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women

  2010cited by this paper
• Definitions / Epidemiology / Risk Factors for Sexual Dysfunctionjsm

  2010cited by this paper
• Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women

  2010influential reference
• Future sexual medicine physiological treatment targets.

  2010cited by this paper
• Standards for clinical trials in male sexual dysfunctions.

  2010cited by this paper
• Women's sexual desire and arousal disorders.

  2010cited by this paper
• Summary of the recommendations on sexual dysfunctions in women.

  2010cited by this paper
• Testosterone treatment of HSDD in naturally menopausal women: the ADORE study

  2010cited by this paper
• Women's motivations for sex: exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders.

  2010cited by this paper
• Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?

  2010cited by this paper
• Female sexual dysfunction: reality or disease-mongering?

  2010cited by this paper
• Recommendations for the management of postmenopausal vaginal atrophy

  2010cited by this paper
• Natural aphrodisiacs.

  2010cited by this paper
• Physiology of women's sexual function: basic knowledge and new findings.

  2010cited by this paper
• Psychological and interpersonal dimensions of sexual function and dysfunction.

  2010cited by this paper
• Sexual activities, sexual and life satisfaction, and successful aging in women.

  2010cited by this paper
• Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment.

  2010cited by this paper
• Endocrine aspects of women's sexual function.

  2010influential reference
• Review: Testosterone therapy for reduced libido in women

  2010cited by this paper
• Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study

  2010influential reference
• Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials

  2010cited by this paper
• Therapeutic options for postmenopausal female sexual dysfunction

  2010influential reference
• Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen

  2009cited by this paper
• Correlates of sexually related personal distress in women with low sexual desire.

  2009cited by this paper
• Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden.

  2009cited by this paper

• Saudi Women's Experiences of Sexual and Relational Changes During the Menopause Transition.

  2025cites this paper
• Tratamento das disfunções sexuais no consultório do ginecologista

  2025cites this paper
• The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause

  2025cites this paper
• Advancing Women’s Health: A Scoping Review of Pharmaceutical Therapies for Female Sexual Dysfunction

  2025cites this paper
• Bringing sex back into the relationship in midlife couples

  2025cites this paper
• Obesity and sexual health: focus on postmenopausal women

  2024cites this paper
• Symptom burden in chronic liver disease

  2024cites this paper
• Sexual health and contraception in the menopause journey.

  2023cites this paper
• Climacteric symptoms, age, and sense of coherence are associated with sexual function scores in women after menopause.

  2023cites this paper
• Female sexual dysfunction and Escitalopram antidepressant

  2022cites this paper
• Sexual dysfunctions and their treatment in liver diseases

  2022cites this paper
• Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

  2022cites this paper
• The Relationship between Sexual Dysfunctions and Depression in Premenopausal Women

  2022cites this paper
• Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?

  2022cites this paper
• Medical Treatment of Female Sexual Dysfunction.

  2022cites this paper
• Review article: current and emerging therapies for the management of cirrhosis and its complications

  2022cites this paper
• Female Sexual Dysfunctions: an overview on the available therapeutic interventions.

  2022cites this paper
• Menopause and female sexual dysfunctions (FSDs).

  2022cites this paper
• Prolactin as a neuroendocrine clue in sexual function of women across the reproductive life cycle: an expert point of view

  2021cites this paper
• Female Sexual Dysfunction in a Third Level Health Facility, Southern Nigeria

  2021cites this paper
• Sexuality, pelvic floor/vaginal health and contraception at menopause.

  2021cites this paper
• The role of hormone therapy in urogenital health after menopause.

  2021cites this paper
• Early Maladaptive Schemas, Sexual Self-Esteem, and Anxiety in Women with Orgasmic Disorders

  2021cites this paper
• Overexpressing miR-122-5p Inhibits the Relaxation of Vaginal Smooth Muscle in Female Sexual Arousal Disorder by Targeting Vasoactive Intestinal Peptide Receptor 1

  2021cites this paper
• Management of hypoactive sexual desire disorder in women in the gynecological setting

  2021cites this paper
• Multifaceted Sexual Dysfunction in Dialyzing Men and Women: Pathophysiology, Diagnostics, and Therapeutics

  2021cites this paper
• Psychiatry and Sexual Medicine: A Comprehensive Guide for Clinical Practitioners

  2021cites this paper
• Natural Testosterone and Sex Drive Optimizer

  2020cites this paper
• The 2020 Menopausal Hormone Therapy Guidelines

  2020cites this paper
• THE KOREAN SOCIETY OF MENOPAUSE PAGES

  2020cites this paper
• Female Sexual Dysfunctions

  2020cites this paper
• Patient–Physician Interactions Regarding Dyspareunia with Endometriosis: Online Survey Results

  2020cites this paper
• TestoBoost version VI Natural Testosterone and Sex Drive Booster

  2019cites this paper
• Investigation of the factors affecting the sexual function in women of reproductive age referred to the Women's Clinic of Hakim Neyshabur Hospital in 2015, Iran

  2019cites this paper
• Effect of Variable Substances on Sexual Function: A Narrative Review

  2019cites this paper
• Sexuality in premature ovarian insufficiency

  2019cites this paper
• What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?

  2019cites this paper
• Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management

  2019cites this paper
• Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine.

  2019cites this paper
• Interface of Female Sexual Dysfunction, Women’s Mental Health, and Psychiatry

  2019cites this paper
• Efficacy of sildenafil citrate in the treatment of female sexual dysfunction

  2019cites this paper
• Testosterone for women: green light for sex, amber light for health?

  2019cites this paper
• Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women

  2019cites this paper
• Non-Hormonal Improvement of FSD by a Combination of Plant Extracts and Amino acids (Lady Prelox®)

  2018cites this paper
• Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics?

  2018cites this paper
• Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study

  2018cites this paper
• miR-137 Affects Vaginal Lubrication in Female Sexual Dysfunction by Targeting Aquaporin-2

  2018cites this paper
• We Have Yet to Illustrate the Tapestry of Sexual Medicine in US Medical Education.

  2018cites this paper
• The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review

  2018cites this paper
• Sexual Dysfunction in Primary Care: An Exploratory Descriptive Analysis of Medical Record Diagnoses.

  2017cites this paper
• Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14.

  2017cites this paper
• Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)

  2017cites this paper
• Controversial Issues in Human Sexuality Research : The State of the Science

  2017cites this paper
• Controversies of Women’s Sexual Arousal and Desire

  2017cites this paper
• Women’s orgasm obstacles: A qualitative study

  2017cites this paper
• Assessment and management of sexual dysfunction in the context of depression

  2017cites this paper
• Evaluation and Treatment of Sexual Disorders Due to Medical Conditions

  2017cites this paper
• Ovarian Physiology and Shortterm Effects of the Menopause

  2016cites this paper
• Pharmacologic management of female sexual dysfunction

  2016influential citation
• 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

  2016cites this paper
• Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL).

  2016cites this paper
• [Female sexual dysfunction: Drug treatment options].

  2016cites this paper
• Systematic review and meta‐analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction

  2016cites this paper
• Sexuality in menopausal women

  2016cites this paper
• Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group *

  2016cites this paper
• To be or not to be in sexual desire: the androgen dilemma

  2015cites this paper
• Urinary and sexual dysfunction rates and risk factors following rectal cancer surgery

  2015cites this paper
• Why are there no FDA-approved treatments for female sexual dysfunction?

  2015cites this paper
• Flibanserin for postmenopausal women-Are they really that different?

  2015cites this paper
• Devices and Methods to Measure Female Sexual Arousal.

  2015cites this paper